Announcements Trials
Browse Landscape

Phase

Phase 3 2

Status

Terminated 1Completed 1

Sponsor Class

INDUSTRY 2

Study Type

Interventional 2

Sponsor

Cancer Type

Other hematologic neoplasm 2Myeloid 2Lymphoid 1

Conditions

Leukemia, Myelogenous, Chronic, BCR-ABL Positive 28Gastrointestinal Stromal Tumors 19Leukemia 16Leukemia, Myeloid, Chronic-Phase 10Precursor Cell Lymphoblastic Leukemia-Lymphoma 7Leukemia, Myeloid 5Bronchiolitis Obliterans Syndrome 5Bone Marrow Diseases 5Philadelphia Chromosome 3Hematologic Diseases 3Sarcoma 2Neoplasms by Histologic Type 2Hematologic Neoplasms 2Translocation, Genetic 1Precursor T-Cell Lymphoblastic Leukemia-Lymphoma 1Piebaldism 1Philadelphia Chromosome Positive Acute Lymphoblastic Leukemia (Ph+ALL) 1Pathologic Processes 1Neoplasms 1Neoplasm Metastasis 1Myeloproliferative Disorders 1Lymphoproliferative Disorders 1Lymphatic Diseases 1Leukemia, Lymphoid 1Leukemia, Biphenotypic, Acute 1Immunoproliferative Disorders 1Immune System Diseases 1Graft vs Host Disease 1Glioblastoma 1Burkitt Lymphoma 1

Interventions

ponatinib 2napabucasin 2Irinotecan 2Imatinib Mesylate 2Gemcitabine 2130-nm albumin-bound paclitaxel 2pralsetinib 1pembrolizumab 1nilotinib 1linifanib 1ibritumomab tiuxetan 1bosutinib 1Vorinostat 1Temozolomide 1Sorafenib 1Rituximab 1Pemetrexed 1Paclitaxel 1Melphalan 1Leucovorin 1Fluorouracil 1FANG vaccine 1Etoposide 1Cytarabine 1Cisplatin 1Carmustine 1Carboplatin 1Bortezomib 1Bevacizumab 1BID protein, human 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
Phase 3 × Neoplasms by Histologic Type × Imatinib Mesylate × Clear all
NCT02130557 2021-05-18

A Multicenter Phase 3, Open-Label Study of Bosutinib Versus Imatinib in Adult Patients With Newly Diagnosed Chronic Phase Chronic Myelogenous Leukemia

Pfizer

Phase 3 Completed
536 enrolled 24 charts 1 FDA
MyeloidOther hematologic neoplasm

Bronchiolitis Obliterans Syndrome, Bone Marrow Diseases, Hematologic Diseases, Leukemia, Leukemia, Myeloid, Neoplasms by Histologic Type, Pathologic Processes, Philadelphia Chromosome, Translocation, Genetic, Leukemia, Myelogenous, Chronic, BCR-ABL Positive

NCT01650805 2014-11-17

Ponatinib in Newly Diagnosed Chronic Myeloid Leukemia (CML) (EPIC)

Ariad Pharmaceuticals

Phase 3 Terminated
307 enrolled 11 charts
LymphoidMyeloidOther hematologic neoplasm

Bone Marrow Diseases, Hematologic Diseases, Immune System Diseases, Immunoproliferative Disorders, Leukemia, Leukemia, Myeloid, Lymphatic Diseases, Lymphoproliferative Disorders, Myeloproliferative Disorders, Neoplasms, Neoplasms by Histologic Type, Leukemia, Myelogenous, Chronic, BCR-ABL Positive

Data powered by HemOnc (CC BY 4.0) Colophon âš¡